Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes

被引:41
|
作者
Reynolds, TM
Twomey, P
Wierzbicki, AS
机构
[1] Queens Hosp, Dept Clin Chem, Burton Upon Trent DE13 0RB, Staffs, England
[2] Wolverhampton Univ, Div Clin Sci, Wolverhampton WV1 1DJ, W Midlands, England
[3] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland
[4] St Thomas Hosp, London, England
来源
JOURNAL OF CARDIOVASCULAR RISK | 2002年 / 9卷 / 04期
关键词
Framingham; risk estimation; primary prevention; coronary heart disease; cardiovascular disease; accuracy; public health; cost-effectiveness;
D O I
10.1097/00043798-200208000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The burden of atherosclerosis has led to treatment prioritization on high-risk individuals without established cardiovascular disease based on risk estimates. We investigated the effects of biological variation in risk factors on risk estimate accuracy and whether current primary prevention screening (risk assessment) models correctly categorize patients. Methods A population of 10 000 'perfect' individuals with 100 simulants affected by biological and analytical variation for systolic blood pressure, total cholesterol, high-density lipoprotein-cholesterol was mathematically modelled. Coronary heart disease (CHID) risks were calculated using the Framingham study algorithm and the mathematical properties of the screening system were evaluated. Results At internationally recommended 10-year CHD risk treatment threshold levels of 15, 20 and 30%, the 95% confidence intervals were +/- 5.1, +/- 6.0 and +/- 6.9% for single-point (singlicate), +/- 3.6, +/- 4.2 and +/- 4.9% for duplicate and +/- 2.8, +/- 3.3 and +/- 3.9% for triplicate estimates respectively (i.e. for singlicate 15% risk, 95% confidence interval is 9.9-20.1%). Consequently, using the 30% risk threshold from the National Service Framework (NSF) for CHID with singlicate estimation, 30% of patients who should receive treatment would be denied it and 20% would receive treatment unnecessarily. Multiple measurements improve precision but cannot absolutely define risk. Blood pressure should be measured to the greatest accuracy possible and not rounded prior to averaging. Conclusions This study suggests biological variation in cardiovascular risk factors has profound consequences on calculated risk for therapeutic decision-making. Current guidelines recommending multiple measurements are usually ignored. Triplicate measurement is required to allow risk to be identified and clinical judgement has to be exercised in interpretation of the results. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:183 / 190
页数:8
相关论文
共 50 条
  • [1] Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk
    Izzo, R.
    de Simone, G.
    Trimarco, V.
    Giudice, R.
    De Marco, M.
    Di Renzo, G.
    De Luca, N.
    Trimarco, B.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2013, 23 (11) : 1101 - 1106
  • [2] The Association of Aspirin With and Without Statin on Cardiovascular Outcomes in Primary Prevention Patients With Diabetes Mellitus
    Muluk, Pallavi
    Zhu, Jianhui
    Thoma, Floyd W.
    Gulati, Martha
    Hay, Eli
    Marroquin, Oscar C.
    Makani, Amber
    Virani, Salim S.
    Ballantyne, Christie M.
    Mulukutla, Suresh R.
    Saeed, Anum
    [J]. CIRCULATION, 2023, 148
  • [3] Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed
    Ferreir, Joao Pedro
    Neves, Joao Sergio
    Saraiva, Francisca
    [J]. JOURNAL OF CARDIAC FAILURE, 2024, 30 (02) : 418 - 420
  • [4] Estimation of cardiovascular risk and detection of subclinical carotid atheromatosis in patients with diabetes without a history of cardiovascular disease
    Masson, Walter
    De Francesca, Salvador
    Molinero, Micaela
    Siniawski, Daniel
    Mulassi, Andres
    Espinoza Morales, Frank
    Huerin, Melina
    Lobo, Martin
    Molinero, Graciela
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (02): : 122 - 129
  • [5] Primary prevention of cardiovascular diseases with statins in patients with diabetes
    Macias Saint-Geronsa, Diego
    de la Fuente Honrubia, Cesar
    de Andres-Trelles, Fernando
    Catala-Lopez, Ferran
    [J]. MEDICINA CLINICA, 2015, 144 (06): : 285 - 287
  • [6] Intensive Lifestyle Medicine for Primary & Secondary Prevention for Cardiovascular Risk Reduction in Patients With Diabetes
    Jafri, S. Hammad
    Imran, Tasnim F.
    Freeman, Andrew M.
    Ornish, Dean
    Wu, Wen-chih
    [J]. CIRCULATION, 2021, 144
  • [7] Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
    Capodanno, Davide
    Angiolillo, Dominick J.
    [J]. CIRCULATION, 2016, 134 (20) : 1579 - 1594
  • [8] Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes
    Chan, Juliana C. N.
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (04) : 344 - 346
  • [9] Statins for primary prevention: problems with cardiovascular-risk estimation?
    Željko Reiner
    [J]. Nature Reviews Cardiology, 2013, 10 : 547 - 547
  • [10] Accuracy of cardiovascular risk estimation
    Reynolds, TM
    Twomey, P
    Wierzbicki, AS
    [J]. CLINICAL CHEMISTRY, 2003, 49 (04) : 706 - 707